Cholinesterase Inhibitors Pose Weight-Loss Risk

This article originally appeared here.
Share this content:
Cholinesterase Inhibitors Pose Weight-Loss Risk
Cholinesterase Inhibitors Pose Weight-Loss Risk

WEDNESDAY, Aug. 12, 2015 (HealthDay News) -- Seniors with dementia newly prescribed cholinesterase inhibitors are at risk for significant weight loss, according to a study published online Aug. 3 in the Journal of the American Geriatrics Society.

Meera Sheffrin, M.D., from University of California at San Francisco, and colleagues utilized National Veterans Affairs data (2007 to 2010) to compare weight loss in 1,188 individuals (≥65 years) with dementia newly prescribed cholinesterase inhibitors and 2,189 propensity-matched individuals newly prescribed other chronic medications.

The researchers found that participants initiated on cholinesterase inhibitors had a higher risk of weight loss than matched controls at 12 months (29.3 percent of those taking cholinesterase inhibitors versus 22.8 percent nonusers; hazard ratio, 1.23). The number needed to harm was 21.2 over one year. Within subgroups there were no significant differences in the risk of weight loss.

"Clinicians should consider the risk of weight loss when prescribing cholinesterase inhibitors," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths